Metformin was found to improve DCM by down-regulating the expression of NLRP3, Caspase-1, and IL-1β through AMP-activated protein kinase (AMPK) in cardiomyocytes treated with high glucose and diabetic mouse models (134). Here, CASP1 is linked to familial dilated cardiomyopathy.